Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAE1 | Q13564 | 4/20 | 0.61 |
| ▸ | UBA3 | Q8TBC4 | 4/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.59 |
| ▸ | SLC29A1 | Q99808 | 3/20 | 0.59 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.52 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.52 |
| ▸ | UBA6 | A0AVT1 | 1/20 | 0.47 |
| ▸ | ATG7 | O95352 | 1/20 | 0.47 |
| ▸ | UBA7 | P41226 | 1/20 | 0.47 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.47 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.44 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1797185 | 0.86 | ADORA3 (0.75) | NAE1UBA3ADORA3SLC29A1ADORA2A | |
| SCHEMBL32661607 | 0.78 | ADORA3 (0.63) | NAE1UBA3ADORA3SLC29A1ADORA2A | |
| SCHEMBL1795974 | 0.78 | ADORA3 (0.75) | ADORA3SLC29A1ADORA2AADORA2BADORA1 | |
| SCHEMBL12566795 | 0.77 | NAE1 (0.78) | NAE1UBA3UBA6ATG7UBA7 | |
| SCHEMBL1797366 | 0.77 | NAE1 (0.78) | NAE1UBA3UBA6ATG7UBA7 | |
| SCHEMBL1797170 | 0.77 | ADORA3 (0.76) | ADORA3SLC29A1ADORA2AADORA2BADORA1 | |
| SCHEMBL1797176 | 0.76 | ADORA3 (0.67) | ADORA3SLC29A1ADORA2AADORA2BADORA1 | |
| SCHEMBL22787594 | 0.76 | NAE1 (1.00) | NAE1UBA3 | |
| SCHEMBL14713231 | 0.75 | ADORA3 (1.00) | ADORA3SLC29A1ADORA2AADORA2BADORA1 | |
| SCHEMBL20626177 | 0.75 | ADORA3 (1.00) | ADORA3SLC29A1ADORA2AADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951810-B2 | Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-20060189636-A1 | Inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189636-A1 | Inhibitors of E1 activating enzymes | ECE1, RNASE1, RCE1 | NAE1 41/4885UBA3 12/4885ADORA3 3584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.